Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MSLE | 6-K | bullish | 6/10 | Satellos announced the USPTO issued U.S. Patent No. 12,747,245 with composition of matter claims covering its lead drug | Oct 5, 2026 |
| PBM | 6-K | neutral | 4/10 | Psyence Biomedical's wholly-owned Texas subsidiary, TIRC, entered a manufacturing services agreement with DEA-registered | Oct 5, 2026 |
| NRIX | PRESS-RELEASE | bullish | 6/10 | Nurix Therapeutics announced a two-year extension of the research term for an undisclosed oncology program under its exi | Oct 5, 2026 |
| HROW | PRESS-RELEASE | bullish | 6/10 | Harrow closed its acquisition of TYRVAYA (varenicline solution) nasal spray from Viatris for $30M in cash at closing, wi | Oct 5, 2026 |
| PBM | PRESS-RELEASE | neutral | 4/10 | Psyence BioMed's Texas subsidiary, TIRC, signed a manufacturing services agreement with DEA-registered Benuvia Operation | Oct 5, 2026 |
| ALEC | PRESS-RELEASE | bullish | 7/10 | Alector granted Genentech exclusive global rights to develop and commercialize AL050, a brain-penetrant GCase ERT for Pa | Oct 5, 2026 |
| LYB | PRESS-RELEASE | neutral | 1/10 | LyondellBasell announced it will report its Q3 results on October 30, 2026. | Oct 5, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a 6-K reporting a $32,350.20 IRS penalty on its U.S. subsidiary for misclassifying a fisc | Oct 5, 2026 |
| ATHE | 6-K | bullish | 6/10 | Alterity Therapeutics presented additional analyses from its Phase 2 trial of ATH434 in Multiple System Atrophy (MSA) at | Oct 5, 2026 |
| PCVX | PRESS-RELEASE | bullish | 7/10 | Vaxcyte announced positive topline results from the OPUS-1 pivotal Phase 3 trial of VAX-31, its 31-valent pneumococcal c | Oct 5, 2026 |
| ALVO | PRESS-RELEASE | bullish | 7/10 | FDA approved a supplement to Alvotech's BLA for AVT02 (SIMLANDI®), enabling drug substance manufacturing in a second pro | Oct 5, 2026 |
| BLRX | EFFECT | bearish | 6/10 | The SEC declared BioLineRx's F-1 registration statement effective on October 2, 2026, enabling the resale of up to 2,023 | Oct 5, 2026 |
| CYDY | EFFECT | bearish | 6/10 | The SEC declared effective CytoDyn's S-3 shelf registration (File No. 333-295250) on October 2, 2026. This allows the co | Oct 5, 2026 |
| CYDY | EFFECT | bearish | 6/10 | Two CytoDyn Inc. registration statements became effective on October 2, 2026: a POS AM (File No. 333-282000) and a new S | Oct 5, 2026 |
| PCVX | PRESS-RELEASE | mixed | 8/10 | Vaxcyte announced it will host a webcast on October 5, 2026 to present topline Phase 3 data from the OPUS-1 trial of VAX | Oct 4, 2026 |
| PULM | S-3/A | bearish | 5/10 | Pulmatrix filed Amendment No. 2 to its S-3 registration statement to register 491,607 shares of common stock for resale | Oct 2, 2026 |
| SYRE | CLUSTER | bearish | 4/10 | Two top executives at Spyre Therapeutics (CEO and CFO) sold a combined $377K of stock on the same day (October 1, 2026) | Oct 2, 2026 |
| ORIC | CLUSTER | neutral | 3/10 | Two ORIC insiders, including the CFO, sold shares in a cluster totaling $223K in open-market sales. The CFO's sale was a | Oct 2, 2026 |
| ADRX | SC 13D | neutral | 5/10 | OrbiMed Advisors LLC and affiliated entities filed a Schedule 13D disclosing beneficial ownership of 14,913,764 shares o | Oct 2, 2026 |
| BSEM | S-1 | bearish | 7/10 | BioStem Technologies filed an S-1 registration statement for the resale of up to 2,224,270 shares by selling stockholder | Oct 2, 2026 |
| TNXP | 8-K | bearish | 6/10 | Tonix received a Paragraph IV ANDA notice from Dr. Reddy's Laboratories seeking FDA approval for a generic version of it | Oct 2, 2026 |
| ORMP | CLUSTER | neutral | 3/10 | Two C-suite insiders at Oramed Pharmaceuticals sold a combined $226K in open-market sales on the same day, with no indic | Oct 2, 2026 |
| VSTM | CLUSTER | bearish | 5/10 | CEO Dan Paterson and CFO Daniel Calkins sold a combined $373K in open-market sales on October 1, 2026, at $8.00/share. T | Oct 2, 2026 |
| DRUG | 6-K | neutral | 2/10 | Bright Minds Biosciences filed a Form 6-K reporting voting results from its annual general meeting held on March 31, 202 | Oct 2, 2026 |
| LNTH | DEFA14A | neutral | 4/10 | Lantheus Holdings filed a DEFA14A providing supplemental disclosures to its definitive proxy statement for the special m | Oct 2, 2026 |
| LNTH | 8-K | neutral | 4/10 | Lantheus filed an 8-K disclosing supplemental proxy disclosures to settle three shareholder lawsuits and 16 demand lette | Oct 2, 2026 |
| IOVA | 3 | neutral | 2/10 | Noah Berkowitz filed a Form 3 initial statement of beneficial ownership after joining Iovance Biotherapeutics as Chief M | Oct 2, 2026 |
| LEEEF | CLUSTER | bullish | 4/10 | Three insiders at Leef Brands Inc., including the CEO and CFO, made open-market purchases totaling $137K at $0.25/share | Oct 2, 2026 |
| XERS | CLUSTER | neutral | 3/10 | Two Xeris Biopharma insiders sold a combined $407K in open-market transactions over a one-week window, with no insider b | Oct 2, 2026 |
| ONC | CLUSTER | bearish | 5/10 | Director Wang Xiaodong executed a large derivative exercise of 434,392 shares (31,028 at $36.9 + 403,364 at $0) and simu | Oct 2, 2026 |